Featured Press Release

  • 10/17/17 7:33 am EDT
    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) today announced that the Company has been issued a new patent related to its RYANODEX® formulation (dantrolene sodium) by the United States Patent and Trademark Office (USPTO). Patent number 9,789,090 will expire in June 2022. The USPTO has now issued seven patents in the RYANODEX family of patents expiring from 2022 to 2025. The ‘090 patent is directed to a method of treatingmore